Italia markets closed

Stereotaxis, Inc. (STXS)

NYSE American - Nasdaq Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
2,2700+0,1000 (+4,61%)
Alla chiusura: 04:00PM EST
2,2500 -0,02 (-0,88%)
Dopo ore: 07:59PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,1700
Aperto2,1500
Denaro2,2400 x 800
Lettera2,3900 x 1100
Min-Max giorno2,1000 - 2,2700
Intervallo di 52 settimane1,5500 - 5,6400
Volume96.245
Media Volume189.126
Capitalizzazione169,897M
Beta (5 anni mensile)1,75
Rapporto PE (ttm)N/D
EPS (ttm)-0,2000
Prossima data utili10 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A5,86
  • GlobeNewswire

    Corewell Health Grows Robotic Program to Treat Heart Rhythm Disorders with Adoption of Stereotaxis’ Genesis System

    ST. LOUIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in robotic technologies for the treatment of cardiac arrhythmias, today announced the successful treatment of patients using the latest Genesis Robotic Magnetic Navigation (RMN) system by physicians of the nationally recognized Fred & Lena Meijer Heart Center, part of Corewell Health in Grand Rapids, Michigan. Electrophysiologists at Corewell Health have established a successful robotic cardiac ablation prog

  • GlobeNewswire

    Stereotaxis to Participate in Piper Sandler 34th Annual Healthcare Conference

    ST. LOUIS, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the Piper Sandler 34th Annual Healthcare Conference. Mr. Fischel will present on Stereotaxis’ business and technology during a Fireside Discussion on Thursday, December 1, 2022, at 9:00 am ET. He will then join a panel discussion on “The Future of Robotic

  • GlobeNewswire

    Stereotaxis Reports 2022 Third Quarter Financial Results

    ST. LOUIS, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2022. “Stereotaxis continues to demonstrate robust commercial and technological progress,” said David Fischel, Chairman and CEO. “We received two system orders in the third quarter, and have already received two additional signed purchase contracts as we